Bioisosteric modifications of 2-arylureidobenzoic acids: Selective noncompetitive antagonists for the homomeric kainate receptor subtype GluR5

被引:41
作者
Valgeirsson, J
Nielsen, EO
Peters, D
Mathiesen, C
Kristensen, AS
Madsen, U
机构
[1] Danish Univ Pharmaceut Sci, Dept Med Chem, DK-2100 Copenhagen, Denmark
[2] Danish Univ Pharmaceut Sci, Dept Pharmacol, DK-2100 Copenhagen, Denmark
[3] NeuroSearch AS, DK-2750 Ballerup, Denmark
关键词
D O I
10.1021/jm030638w
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
2-Arylureidobenzoic acids (AUBAs) have recently been presented as the first series of selective noncompetitive GluR5 antagonists. In this paper we have modified the acidic moiety of the AUBAs by introducing different acidic and neutral groups, and similarly, we have replaced the urea linker of the AUBAs with other structurally related linkers. Replacing the acid with neutral substituents led to inactive compounds in all instances, showing that an acidic moiety is necessary for activity. Replacing the carboxylic moiety in 2a with a sulfonic acid (5c) or a tetrazole ring (5d) improved the potency at GluR5 receptors (compounds 5c and 5d showed IC50 values of 1.5 and 2.0 muM, respectively, compared to compound 2a with IC50 = 4.8 muM). Compound 5c did not show improved in vivo activity in the ATPA rigidity test compared to 2a, whereas compound 5d was 4 times more potent than 2a. All compounds wherein the urea linker had been replaced showed lower or no activity. The results described extend the knowledge of structure-activity relationships for the AUBAs, and compound 5d may prove to be a good candidate for studying GluR5 receptors in vitro and in vivo.
引用
收藏
页码:6948 / 6957
页数:10
相关论文
共 34 条
[21]   Decahydroisoquinolines: novel competitive AMPA/kainate antagonists with neuroprotective effects in global cerebral ischaemia [J].
O'Neill, MJ ;
Bond, A ;
Ornstein, PL ;
Ward, MA ;
Hicks, CA ;
Hoo, K ;
Bleakman, D ;
Lodge, D .
NEUROPHARMACOLOGY, 1998, 37 (10-11) :1211-1222
[22]   LY377770, a novel iGlu5 kainate receptor antagonist with neuroprotective effects in global and focal cerebral ischaemia [J].
O'Neill, MJ ;
Bogaert, L ;
Hicks, CA ;
Bond, A ;
Ward, MA ;
Ebinger, G ;
Ornstein, PL ;
Michotte, Y ;
Lodge, D .
NEUROPHARMACOLOGY, 2000, 39 (09) :1575-1588
[23]   Structure-activity studies of 6-substituted decahydroisoquinoline-3-carboxylic acid AMPA receptor antagonists .2. Effects of distal acid bioisosteric substitution, absolute stereochemical preferences, and in vivo activity [J].
Ornstein, PL ;
Arnold, MB ;
Allen, NK ;
Bleisch, T ;
Borromeo, PS ;
Lugar, CW ;
Leander, JD ;
Lodge, D ;
Schoepp, DD .
JOURNAL OF MEDICINAL CHEMISTRY, 1996, 39 (11) :2232-2244
[24]   (3SR,4ARS,6SR,8ARS)-6-(1H-TETRAZOL-5-YL)DECAHYDROISOQUINOLINE-3-CARBOXYLIC ACID, A NOVEL, COMPETITIVE, SYSTEMICALLY ACTIVE NMDA AND AMPA RECEPTOR ANTAGONIST [J].
ORNSTEIN, PL ;
ARNOLD, MB ;
ALLEN, NK ;
LEANDER, JD ;
TIZZANO, JP ;
LODGE, D ;
SCHOEPP, DD .
JOURNAL OF MEDICINAL CHEMISTRY, 1995, 38 (25) :4885-4890
[25]   Glutamate in CNS disorders as a target for drug development: An update [J].
Parsons, CG ;
Danysz, W ;
Quack, G .
DRUG NEWS & PERSPECTIVES, 1998, 11 (09) :523-569
[26]   Binding interactions between 3-aryl-1,2,4-oxadiazol-5-ones and a trisimidazoline base [J].
Reichert, A ;
Fröhlich, R ;
Ferguson, R ;
Kraft, A .
JOURNAL OF THE CHEMICAL SOCIETY-PERKIN TRANSACTIONS 1, 2001, (11) :1321-1328
[27]   Kainate GluR5 receptor subtype mediates the nociceptive response to formalin in the rat [J].
Simmons, RMA ;
Li, DL ;
Hoo, KH ;
Deverill, M ;
Ornstein, PL ;
Iyengar, S .
NEUROPHARMACOLOGY, 1998, 37 (01) :25-36
[28]  
Smolders D, 2002, JBR-BTR, V85, P154
[29]  
TURSKI L, 1992, J PHARMACOL EXP THER, V260, P742
[30]   2-arylureidobenzoic acids: Selective noncompetitive antagonists for the homomeric kainate receptor subtype GluR5 [J].
Valgeirsson, J ;
Nielsen, EO ;
Peters, D ;
Varming, T ;
Mathiesen, C ;
Kristensen, AS ;
Madsen, U .
JOURNAL OF MEDICINAL CHEMISTRY, 2003, 46 (26) :5834-5843